Abstract
Background Coronavirus disease 2019 (COVID-19) can lead to long-term cardiopulmonary symptoms and is associated to coronary microvascular dysfunction (CMD). However, long-term data on CMD following severe COVID-19 are lacking.
Objective To determine long-term left ventricular (LV) function and presence of CMD after severe COVID-19, utilizing cardiovascular magnetic resonance (CMR) and stress perfusion mapping.
Methods Hospitalized COVID-19 patients underwent CMR at 10 months follow-up (1.5T Aera, Siemens Healthineers) including cine imaging, native T1 and T2, extracellular volume, and adenosine stress perfusion mapping. Clinical data were obtained from patient records. Patients were compared to volunteers without symptomatic ischemic heart disease (IHD).
Results COVID-19 patients (n=37, age 56±12 years, 76% male) and volunteers (n=22, age 51±13 years, 55% male, p=ns for both) were included. COVID-19 patients demonstrated reduced stress perfusion (2.8±0.81 vs 3.4±0.69 ml/min/g, p=0.003), impaired global longitudinal strain (GLS, −17±2 vs −19±2 %, p=0.003) and global circumferential strain (GCS, −16±3 vs −19±3 %, p=0.001). There were no differences in stress perfusion or myocardial perfusion reserve between COVID-19 patients with or without cardiovascular risk factors or cardiac symptoms.
Conclusion COVID-19 patients exhibit long-term reduced stress perfusion indicating CMD, and impaired LV function by GLS and GCS. Lack of variation in stress perfusion between patients with and without cardiovascular risk factors suggests that CMD may be a consequence of severe COVID-19, warranting further investigation to elucidate mechanisms, and guide potential therapeutic interventions.
Competing Interest Statement
Sanofi Genzyme AB has previously awarded JN minor speaker compensation for work unrelated to this study. PK receives research support (source codes) from Siemens Healthineers. Karolinska University Hospital has a research and development agreement with Siemens Healtineers. The rest of the authors declare no competing interests.
Funding Statement
Funding was provided by the Swedish Research Council, Swedish Heart and Lung Foundation, the Swedish Society of Medicine, the Stockholm County Council and Karolinska Institutet. MS has received research grants from Dysautonomia International, Swedish Research Foundation, Swedish Virology Society.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were granted ethical approval by the Swedish Ethical Review Authority (Dnr 2021-03293, 2022-0695, 2020-02397).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- ARDS
- Acute Respiratory Distress Syndrome
- CMD
- Coronary Microvascular Dysfunction
- CMR
- Cardiovascular Magnetic Resonance Imaging
- COVID-19
- Coronavirus disease 2019
- hs-TnT
- High Sensitivity Troponin T
- IHD
- Ischemic Heart Disease
- MPR
- Myocardial Perfusion Reserve
- PAP
- Pulmonary Artery Pressure
- PACS
- Post-Acute COVID-19 Syndrome
- PET
- Positron Emission Tomography
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.